Clinical Analysis Of Chemotherapy Of 177 Metastatic Colorectal Cancer Patients

Objective:To explore the clinical efficacy of metastatic colorectal patients with different chemotherapy regimens, analysis the rationality and "quantitative" issue in the chemotherapy process.Material and Methods:Based on the inclusion and exclusion criteria, with retrospective analysis by screening metastatic colorectal cancer patients treated at the Affiliated Tumor Hospital of Guangxi Medical University between March 2010 and March 2015,177 cases met the inclusion criteria (24.5%) were selected as research subjects. The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 rules was used to evaluate the effect of chemotherapy, the respond was divided into complete respond (CR), partial response (PR), stable disease (SD) and progressive disease (PD), (CR+PR) was used to calculate efficiency RR and (CR+PR+SD) to disease control rate DCR. To explore the clinical efficacy of metastatic colorectal patients with different chemotherapy regimens, analysis the rationality and "quantitative" issue in the chemotherapy process.Results:1, Among collected 177 metastatic colorectal cancer patients,132 cases (74.6%) receiving FOLFOX regimen, after the first time to evaluate the efficacy of chemotherapy, PR was 53 cases (40.2%), CR 1 case (0.7%), SD 60 cases (45.5%) and PD 18 cases (13.6%), RR was 40.9%, DCR 86.4%; 54 cases was valid after the first time efficacy evaluation of chemotherapy, of which 37 cases (68.5%) continued chemotherapy with the original regimen, re-assess the efficacy of PR was 8 cases (21.6%), CR 1 case (2.7%), SD 21 cases (56.8%) and PD 7 cases (18.9%), RR was 24.3%, DCR 81.1%;2, Among 132 patients receiving FOLFOX regimen,60 patients was SD after the first time efficacy evaluation of chemotherapy, of which 15 patients (25%) continued chemotherapy with the original regimen, re-assess the efficacy of PR was 5 cases (33.3%), CR 0 case (0.0%), SD 6 cases (40%) and PD 4 cases (26.7%), RR was 33.3%, DCR was 73.3%.3,45 cases (25.4%) receiving XELOX regimen, after the first time to evaluate the efficacy of chemotherapy, PR was 20 cases (44.5%), CR 0 case (0.0%), SD 19 cases (42.2%) and PD 6 cases (13.3%), RR was 44.5%, DCR 86.7%; 20 cases was valid after the first time efficacy evaluation of chemotherapy, of which 12 patients (60%) continued chemotherapy with the original regimen, re-assess the efficacy of PR was 1 case (8.3%), CR 0 case (0.0%), SD 10 cases (83.4%) and PD 1 case (8.3%), RR was 8.3%, DCR 91.7%;4, Among 45 patients receiving XELOX regimen,19 patients was SD after the first time efficacy evaluation of chemotherapy, of which 8 patients (42.1%) continued chemotherapy with the original regimen, re-assess the efficacy of PR was 1 case (12.5%), CR 0 case (0.0%), SD 4 cases (50%) and PD 3 cases (37.5%), RR was 12.5%, DCR 62.5%.5, Among patients treated with FOLFOX regime was valid after the first time efficacy evaluation of chemotherapy,2-4 (average 3.32±0.89) cycles of chemotherapy were needed, and 2-4 (average 3.05±1.19) cycles of chemotherapy were needed in patients treated with XELOX regime.6, There was no significant difference (P> 0.05) in RR and DCR after the first time efficacy evaluation of chemotherapy in both treatments, the first time efficacy evaluation of chemotherapy is more efficient than the re-assessed patients treated with XELOX regime, (P<0.05), whereas no significant difference with was found in FOLFOX regime (P> 0.05).Conclusion:1.Similar efficacy for the first time to assess the efficacy of chemotherapy was found in both FOLFOX and XELOX regime.2.The best time of single chemotherapy used is 2-4 cycles of chemotherapy; union of two or more chemotherapy regimens alternating sequential application, the availability of better treatment effect is indeed worthy of further exploration.3.Patients of not respond to chemotherapy with early (<4 cycles of chemotherapy) continued to treat with original regimen, which will not benefit significantly, and the first assessment of SD patients continued the original regimen are more vulnerable to disease progression.4.For metastatic colorectal cancer patients with a continuous multi-cycle chemotherapy in a single regimen, whether it is for the first time to assess the efficacy of active or SD patients are not necessarily the best choice.